Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00361309 · ClinicalTrials.gov registry record · Phase 2
SU011248 in Advanced Hepatocellular Carcinoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00361309: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00361309 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00361309, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The main purpose of this study is to begin to collect information and try to learn whether SU011248 works in treating patients with advanced liver cancer. Laboratory studies have shown that SU011248 may block the growth of blood vessels in tumors, which may prevent tumors from growing any further.
Interventions
- DRUG SU011248
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00361309
The ClinicalTrials.gov registry entry for NCT00361309 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SU011248 is the first listed.
NCT00361309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00361309 about?
NCT00361309 is a clinical study titled "SU011248 in Advanced Hepatocellular Carcinoma". The main purpose of this study is to begin to collect information and try to learn whether SU011248 works in treating patients with advanced liver cancer. Laboratory studies have shown that SU011248 may block the growth of blood vessels in tumors, which may prevent tumors from growing any further.
What is the current status of trial NCT00361309?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2006-04. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00361309?
The interventions under investigation include: SU011248 (DRUG).
Who is sponsoring clinical trial NCT00361309?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.